Reproducibility of GMP-compliant production of therapeutic stressed peripheral blood mononuclear cell-derived secretomes, a novel class of biological medicinal products
Open Access
- 3 January 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Stem Cell Research & Therapy
- Vol. 11 (1), 1-16
- https://doi.org/10.1186/s13287-019-1524-2
Abstract
The recent concept of secretome-based tissue regeneration has profoundly altered the field of regenerative medicine and offers promising novel therapeutic options. In contrast to medicinal products with a single active substance, cell-derived secretomes comprise pleiotropic bioactive ingredients, representing a major obstacle for reproducible drug product efficacy and warranting patient safety. Good manufacturing practice (GMP)-compliant production guarantees high batch-to-batch consistency and reproducible efficacy of biological medicinal products, but different batches of cellular secretomes produced under GMP have not been compared yet, and suitable quality control parameters have not been established. To this end, we analyzed diverse biological and functional parameters of different batches produced under GMP of the secretome obtained from γ-irradiated peripheral blood mononuclear cells with proven tissue regenerative properties in infarcted myocardium, stroke, spinal cord injury, and skin wounds. We quantified key secretome ingredients, including cytokines, lipids, and extracellular vesicles, and functionally assessed potency in tube formation assay, ex vivo aortic ring sprouting assay, and cell-based protein and reporter gene assays. Furthermore, we determined secretome stability in different batches after 6 months of storage at various ambient temperatures. We observed that inter-batch differences in the bioactive components and secretome properties were small despite considerable differences in protein concentrations and potencies between individual donor secretomes. Stability tests showed that the analytical and functional properties of the secretomes remained stable when lyophilisates were stored at temperatures up to + 5 °C for 6 months. We are the first to demonstrate the consistent production of cell-derived, yet cell-free secretome as a biological medicinal product. The results from this study provide the basis for selecting appropriate quality control parameters for GMP-compliant production of therapeutic cell secretomes and pave the way for future clinical trials employing secretomes in tissue regenerative medicine.Keywords
Funding Information
- Österreichische Forschungsförderungsgesellschaft (852748)
- Vienna Business Agency (2343727)
This publication has 50 references indexed in Scilit:
- Secretome of apoptotic peripheral blood cells (APOSEC) confers cytoprotection to cardiomyocytes and inhibits tissue remodelling after acute myocardial infarction: a preclinical studyBasic Research in Cardiology, 2011
- Malignant Tumor Formation After Transplantation of Short-Term Cultured Bone Marrow Mesenchymal Stem Cells in Experimental Myocardial Infarction and Diabetic NeuropathyCirculation Research, 2011
- Intravenous and intramyocardial injection of apoptotic white blood cell suspensions prevents ventricular remodelling by increasing elastin expression in cardiac scar tissue after myocardial infarctionBasic Research in Cardiology, 2011
- Aggregation of human mesenchymal stromal cells (MSCs) into 3D spheroids enhances their antiinflammatory propertiesProceedings of the National Academy of Sciences of the United States of America, 2010
- Irradiated cultured apoptotic peripheral blood mononuclear cells regenerate infarcted myocardiumEuropean Journal of Clinical Investigation, 2009
- Bone marrow cells are a rich source of growth factors and cytokines: implications for cell therapy trials after myocardial infarctionEuropean Heart Journal, 2008
- Secreted frizzled related protein 2 (Sfrp2) is the key Akt-mesenchymal stem cell-released paracrine factor mediating myocardial survival and repairProceedings of the National Academy of Sciences of the United States of America, 2007
- Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanismsAmerican Journal of Physiology-Renal Physiology, 2005
- Adult vasculogenesis occurs through in situ recruitment, proliferation, and tubulization of circulating bone marrow–derived cellsBlood, 2005
- Transplanted bone marrow cells localize to fracture callus in a mouse modelJournal of Orthopaedic Research, 2002